Skip to content

On March 6, 2020, the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC) jointly issued seven warning letters to companies making alleged unauthorized claims related to the prevention or treatment of the Coronavirus Disease 2019 (COVID-19). In addition to issuing the joint warning letters, the FDA issued a press release announcing the actions taken and pages on its website (www.fda.gov) dedicated to COVID-19 issues. The FDA also posted an album of pictures of the alleged fraudulent products being promoted for the treatment or prevention of COVID-19.

Read the full GT Alert, “FDA and FTC Warn Companies for Unauthorized Coronavirus Disease 2019 (COVID-19) Claims.”

Tags: advertising, consumer products, Consumer protection, consumer safety, deceptive advertising, FDA, Federal Trade Commission, Food and Drug Administration, FTC, Greenberg Traurig, GT Insight
Print:
Email this postTweet this postLike this postShare this post on LinkedIn
Photo of James R. Prochnow James R. Prochnow

Jim Prochnow concentrates his practice on Food and Drug Administration (FDA), Federal Trade Commission (FTC), and Drug Enforcement Agency (DEA) actions, advice and related litigation, which includes import detentions, government inspections, investigations and defense of class actions. He also counsels clients about regulatory

…

Jim Prochnow concentrates his practice on Food and Drug Administration (FDA), Federal Trade Commission (FTC), and Drug Enforcement Agency (DEA) actions, advice and related litigation, which includes import detentions, government inspections, investigations and defense of class actions. He also counsels clients about regulatory issues associated with cosmetics, dietary supplements, homeopathic drugs, Over-the-counter (OTC) drugs, the use of CBD oil in products, the protocols and contracts associated with clinical trials, and cGMP compliance.

Read more about James R. Prochnow
Show more Show less
Photo of Nancy E. Taylor Nancy E. Taylor

Nancy Taylor is Co-Chair of the Health Care & FDA Practice and focuses her practice on health and FDA related matters. She has broad experience working with providers, plans, employers, private equity firms, and FDA regulated companies. She advises clients on health care

…

Nancy Taylor is Co-Chair of the Health Care & FDA Practice and focuses her practice on health and FDA related matters. She has broad experience working with providers, plans, employers, private equity firms, and FDA regulated companies. She advises clients on health care transactions, health and FDA regulatory policy and compliance, and responding to Congressional and Administration investigations and audits. Prior to joining Greenberg Traurig, Nancy served 10 years as Health Policy Director for a Senate Committee and worked on a number of significant health and FDA laws. She also served as CEO of a start-up medical device company, where she obtained eight product clearances, including securing reimbursement coverage for each product.

Read more about Nancy E. Taylor
Show more Show less
Photo of Justin J. Prochnow Justin J. Prochnow

Justin J. Prochnow assists companies with regulatory, business, and legal needs in the beverage, food, dietary supplement, cosmetic, medical device, and OTC industries. Justin works closely with companies to ensure regulatory compliance with statutes and regulations enforced by the Food and Drug Administration,

…

Justin J. Prochnow assists companies with regulatory, business, and legal needs in the beverage, food, dietary supplement, cosmetic, medical device, and OTC industries. Justin works closely with companies to ensure regulatory compliance with statutes and regulations enforced by the Food and Drug Administration, the Federal Trade Commission and other regulatory agencies. This includes the review of product labels, labeling, advertising, websites and other marketing materials. Justin assists companies with responding to governmental and regulatory actions, including FDA inspections and warning letters, FTC Civil Investigative Demands, and ASRC and NAD cases. He prepares and reviews business documents for industry members, including consulting, manufacturing, supply and distribution agreements. Justin and his team also defend industry companies from both governmental agencies and civil litigators in litigation ranging from breach of contract cases to the growing number of class actions alleging false and misleading advertising.

Meet Justin Prochnow

Read more about Justin J. ProchnowJustin's Linkedin ProfileJustin's Twitter Profile
Show more Show less
Related Posts
 Consumer Product Safety Commission Proposes First Safety Requirements for Nursing Pillows
September 29, 2023
coffee
Trademark Owner Liable to Consumer for Product Defect, European Court of Justice Rules
September 27, 2022
shutterstock_380464495
7th Circuit Lowers Removal Hurdle for Defendants That Assisted the Feds
July 9, 2020